Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
The German drug maker Boehringer Ingelheim has acquired Northern Biologics, a Canadian developer of antibodies targeting the tumor microenvironment, for an undisclosed sum. One of Northern’s two experimental antibodies inhibits a key protein in the microenvironment, causing a tumor to become susceptible to immune system attack. Separately, Boehringer will collaborate with the Swiss firm CDR-Life on developing antibody fragment therapies that treat geographic atrophy, a retinal disease.
This article has been sent to the following recipient: